Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 8/20 | 1.00 |
| ▸ | CYSLTR2 | Q9NS75 | 7/20 | 1.00 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.52 |
| ▸ | LTB4R | Q15722 | 6/20 | 0.47 |
| ▸ | LTB4R2 | Q9NPC1 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8464474 | 1.00 | CYSLTR1 (1.00) | CYSLTR1CYSLTR2PTGER4LTB4RLTB4R2 | |
| SCHEMBL1223364 | 1.00 | CYSLTR1 (1.00) | CYSLTR1CYSLTR2PTGER4LTB4RLTB4R2 | |
| SCHEMBL8829350 | 0.93 | CYSLTR1 (0.88) | CYSLTR1CYSLTR2PTGER4LTB4RLTB4R2 | |
| SCHEMBL8829348 | 0.93 | CYSLTR1 (0.88) | CYSLTR1CYSLTR2PTGER4LTB4RLTB4R2 | |
| SCHEMBL8829354 | 0.93 | CYSLTR1 (0.88) | CYSLTR1CYSLTR2PTGER4LTB4RLTB4R2 | |
| SCHEMBL10442686 | 0.92 | CYSLTR1 (0.85) | CYSLTR1CYSLTR2PTGER4LTB4RLTB4R2 | |
| SCHEMBL8462615 | 0.92 | CYSLTR1 (0.85) | CYSLTR1CYSLTR2PTGER4LTB4RLTB4R2 | |
| SCHEMBL10598407 | 0.92 | CYSLTR1 (0.85) | CYSLTR1CYSLTR2PTGER4LTB4RLTB4R2 | |
| SCHEMBL8466061 | 0.92 | CYSLTR1 (0.85) | CYSLTR1CYSLTR2PTGER4LTB4RLTB4R2 | |
| SCHEMBL8462621 | 0.92 | CYSLTR1 (0.85) | CYSLTR1CYSLTR2PTGER4LTB4RLTB4R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4987231-A | Optical resolution method for 3R-(3-carboxybenzyl)-6-(5-fluoro-2-benzothiazolyl)methoxy-4R-chromanol | PFIZER INC. (US) | 1991-01-22 | — | — | US | claimed |
| US-8772288-B2 | Substituted spiro[cycloalkyl-1,3′-indo]-2′(1′H)-one derivatives and their use as P38 mitogen-activated kinase inhibitors | ALMIRALL, S.A. (ES) | 2014-07-08 | — | — | US | disclosed |
| EP-2280943-B1 | NEW SUBSTITUTED SPIRO[CYCLOALKYL-1,3'-INDO]-2'(1'H)-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS | ALMIRALL SA (ES) | 2013-11-06 | — | — | EP | disclosed |
| US-8450341-B2 | Substituted indolin-2-one derivatives and their use as P38 mitogen-activated kinase inhibitors | ALMIRALL, S.A. (ES) | 2013-05-28 | — | — | US | disclosed |
| US-8334294-B2 | 4,8-diphenyl-polyazanaphthalene derivatives | ALMIRALL, S.A. (ES) | 2012-12-18 | — | — | US | disclosed |
| EP-2498775-A1 | NEW 7-PHENYL-[1,2,4]TRIAZOLO[4,3-A]PYRIDIN-3(2H)-ONE DERIVATIVES | Almirall S.A. (ES) | 2012-09-19 | — | — | EP | disclosed |
| US-20120225904-A1 | New 7-Phenyl-[1,2,4]triazolo[4,3-a]Pyridin-3(2H)-One Derivatives | ALMIRALL, S.A. (ES) | 2012-09-06 | — | — | US | disclosed |
| US-8258122-B2 | 3-([1,2,4]triazolo[4,3-a]pyridin-7-yl)benzamide derivatives | ALMIRALL, S.A. (ES) | 2012-09-04 | — | — | US | disclosed |
| EP-2146988-B1 | NEW 4,8-DIPHENYL-POLYAZANAPHTHALENE DERIVATIVES | ALMIRALL SA (ES) | 2012-08-15 | — | — | EP | disclosed |
| EP-2280953-B1 | NEW SUBSTITUTED INDOLIN-2-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS | ALMIRALL SA (ES) | 2012-05-09 | — | — | EP | disclosed |
| US-5998451-A | LIPOXYGENASE INHIBITORS | PFIZER INC (US) | 1999-12-07 | — | — | US | disclosed |
| EP-0533695-B1 | IMIDAZO (4,5-c) PYRIDINES WITH PAF ANTAGONIST ACTIVITY | PFIZER (US) | 1994-10-05 | — | — | EP | disclosed |
| US-5322847-A | Inhibit platelet activating factor, block leukotriene D4 receptors | PFIZER INC. (US) | 1994-06-21 | — | — | US | disclosed |
| EP-0533695-A1 | IMIDAZO (4,5-c) PYRIDINES WITH PAF ANTAGONIST ACTIVITY. | PFIZER (US) | 1993-03-31 | — | — | EP | disclosed |
| WO-1991017163-A1 | IMIDAZO (4,5-c) PYRIDINES WITH PAF ANTAGONIST ACTIVITY | PFIZER INC. (US) | 1991-11-14 | — | — | WO | disclosed |
| US-5059609-A | Lipoxygenase inhibitors; leukotriene receptor blockers; psoriasis; antiulcer agents and myocardial infarctions | PFIZER INC. (US) | 1991-10-22 | — | — | US | disclosed |
| EP-0411813-A1 | Optical resolution method for 3S-(3-carboxybenzyl)-6-(5-fluoro-2-benzothiazolyl)methoxy-4S-chromanol | PFIZER INC. (US) | 1991-02-06 | — | — | EP | disclosed |
| US-4987231-A | Optical resolution method for 3R-(3-carboxybenzyl)-6-(5-fluoro-2-benzothiazolyl)methoxy-4R-chromanol | PFIZER INC. (US) | 1991-01-22 | — | — | US | disclosed |
| US-4987231-A | Optical resolution method for 3R-(3-carboxybenzyl)-6-(5-fluoro-2-benzothiazolyl)methoxy-4R-chromanol | PFIZER INC. (US) | 1991-01-22 | — | — | US | disclosed |
| US-4987231-A | Optical resolution method for 3R-(3-carboxybenzyl)-6-(5-fluoro-2-benzothiazolyl)methoxy-4R-chromanol | PFIZER INC. (US) | 1991-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225904-A1 | New 7-Phenyl-[1,2,4]triazolo[4,3-a]Pyridin-3(2H)-One Derivatives | MAPK7, MAPK1, MAP3K7 | CYSLTR1 2683/4885CYSLTR2 1899/4885PTGER4 1209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.